SILVER SPRING
Tzield indication expanded to pediatric type 1 diabetes
- Sponsor
- Sanofi $SNY
- Drug
- Tzield · teplizumab-mzwv
- Indication
- stage 3 type 1 diabetes
FDA approved Tzield (teplizumab-mzwv) for delaying stage 3 type 1 diabetes onset in children as young as one year old.
What this means
Tzield is an antibody drug that targets immune cells to delay the progression of type 1 diabetes in children. Today FDA expanded its approval to include kids as young as one year old who are at risk of developing full-blown diabetes. This decision could help protect more young children from needing insulin injections by slowing the disease's advance during its earliest stages.
Drug Watch — recent news on Tzield
- newsGP - Type 1 diabetes drug unable to secure PBS listing - Royal Australian College of General Practitioners (RACGP)
- Type 1 Diabetes Families Make the Case for Earlier Action at Friends for Life 2026 - Orlando Magazine
- Quest Diagnostics Team Tests Impact of Teplizumab’s FDA Approval on Screening for Type 1 Diabetes - Quest Diagnostics Newsroom
- Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence - BioSpace
- Sanofi survey uncovers Type 1 diabetes misconceptions and screening gaps - Fierce Pharma